Company name Alkermes Public Limited Company
Ticker ALKS
Class period February 17, 2017 – November 1, 2018
Lead plaintiff deadline February 25, 2019
Court Eastern District of New York

According to the Complaint, the company made false and misleading statements to the market.  Alkermes was advised by the FDA to use a specific protocol with its New Drug Application submission for ALKS 5461. The company subsequently failed to follow the protocol.  After reviewing the submission, an FDA advisory committee decided in a 21 to 2 vote against approving ALKS 5461.  Based on these facts, the company’s public statements were false and materially misleading throughout the class period.